Intellia Therapeutics(NASDAQ:NTLA)报告季度每股亏损1.27美元，优于分析师预期的亏损1.36美元，增幅为6.62%。这相比去年同期每股亏损1.46美元，增加了13.01%。该公司报告季度销售额为1287万美元，优于分析师预期的853万美元，增幅达50.89%。这相比去年同期的负192万美元，增加了771.57%。
以上内容来自Benzinga Earnings专栏，原文如下：
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.36) by 6.62 percent. This is a 13.01 percent increase over losses of $(1.46) per share from the same period last year. The company reported quarterly sales of $12.87 million which beat the analyst consensus estimate of $8.53 million by 50.89 percent. This is a 771.57 percent increase over sales of $(1.92 million) the same period last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。